Researchers from CannTrust Holdings Inc (CannTrust) and Australia’s Gold Coast University Hospital (Gold Coast) will collaborate to conduct a randomized, double blind, placebo-controlled clinical trial to determine the efficacy of CannTrust cannabidiol (CBD) oil capsules in slowing the disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). The investigators will assess patient safety and tolerability.
ALS is a fatal disease with no cure. In the United States it is estimated that 6,000 are diagnosed with the disease each year and approximately 20,000 struggle with the disease at any one time. For more on ALS see link to the ALS Association: http://www.alsa.org/news/media/quick-facts.html
The lead researcher will be Dr. Arman Sabet, Gold Coast Neurologist.
View article here